CoChat

Therapeutic potential of omega-3 fatty acids supplementation in a mouse model of dry macular degeneration

Open access

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Abstract

Purpose To evaluate the therapeutic effects of omega-3 (ω-3) and omega-6 (ω-6) fatty acids in the CCL2−/− model of dry age-related macular degeneration (AMD). The blood level of eicosapentaenoic acid (EPA) and arachidonic acid (AA) served to adjust the treatment dosage (AA/EPA=1–1.5). Methods Nine-month-old animals were allocated to different groups: (A) C57BL/6 untreated , (B) CCL2−/− untreated, (C) CCL2−/− treated with ω-3+ω-6, and (D) CCL2−/− treated with ω-3. Treatment was daily administered by gavage for 3 months. Fatty acids analysis was performed and retinas were histologically examined. Three-month-old wild type mice were used for comparison purposes. Real-time PCR and Western blot were performed for retinal inflammatory mediators. Results Increased EPA and decreased AA levels were observed in both blood and retinas in the treatment groups. The outer nuclear layer thickness was increased in groups C (45.0±3.9 µm) and D (62.8±4.9 µm), compared with groups B (65.6±3.0 µm) and A (71.1±4.2 µm), and in younger mice, it was 98.0±3.9 µm. A decrease in NF-κB expression was noted in the treatment groups. Interleukin (IL) 18 protein levels demonstrated a significant reduction in the ω-3-treated group only. Conclusion Supplementation with ω-3+ω-6 or ω-3 alone (AA/EPA=1–1.5) suggests a protective mechanism in the CCL2−/− animal model of dry AMD, with a more beneficial effect when ω-3 are used alone. Our findings indicated that inflammation is not the only determining factor; perhaps a regenerative process might be involved following administration of ω-3 fatty acids.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjophth-2016-000056

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Fatty acid analysis from blood samples collected on (A) D0, (B) D30 and (C) D90 from C57BL/6 untreated group, CCL2−/− untreated group, CCL2−/− ω-3+ω-6-treated group and CCL2−/− ω-3-treated group. (D) The AA/EPA ratio is shown in each group for D0, D30 and D90. The proportion of DGLA, AA, EPA and DHA is expressed as the mean±SEM (n=22–24).
Figure 1 Fatty acid analysis from blood samples collected on (A) D0, (B) D30 and (C) D90 from C57BL/6 untreated group, CCL2−/− untreated group, CCL2−/− ω-3+ω-6-treated group and CCL2−/− ω-3-treated group. (D) The AA/EPA ratio is shown in each group for D0, D30 and D90. The proportion of DGLA, AA, EPA and DHA is expressed as the mean±SEM (n=22–24).CC BY · PubMed Central
Figure 2 Fatty acid analysis from retina samples collected on D90 from groups A, C57BL/6 untreated; B, CCL2−/− untreated; C, CCL2−/− treated with ω-3+ω-6; and D, CCL2−/− treated with ω-3. The proportion of DGLA, AA, EPA and DHA is expressed as the mean±SEM (n=4).
Figure 2 Fatty acid analysis from retina samples collected on D90 from groups A, C57BL/6 untreated; B, CCL2−/− untreated; C, CCL2−/− treated with ω-3+ω-6; and D, CCL2−/− treated with ω-3. The proportion of DGLA, AA, EPA and DHA is expressed as the mean±SEM (n=4).CC BY · PubMed Central
Figure 3 (1) Representative ocular photomicrographs of groups A, C57BL/6 untreated; B, CCL2−/− untreated; C, CCL2−/− treated with ω-3+ω-6; and D, CCL2−/− treated with ω-3. Cryosections were stained for cone arrestin (red), rhodopsin (green) and TO-PRO-3 iodide (blue) for nuclear staining. Samples were examined by a Leica TCS SP5 confocal microscope (original magnification 100×, scale bar=50 µm). Arrow indicates retinal ONL. (2) Measurements of the ONL were performed at different fields around the entire retinal section (centre, middle and periphery). ImageJ software was used to calculate the ONL thickness, and the mean ONL thickness of the entire retina was compared among the different groups. Data represent the mean±SEM (n=5).
Figure 3 (1) Representative ocular photomicrographs of groups A, C57BL/6 untreated; B, CCL2−/− untreated; C, CCL2−/− treated with ω-3+ω-6; and D, CCL2−/− treated with ω-3. Cryosections were stained for cone arrestin (red), rhodopsin (green) and TO-PRO-3 iodide (blue) for nuclear staining. Samples were examined by a Leica TCS SP5 confocal microscope (original magnification 100×, scale bar=50 µm). Arrow indicates retinal ONL. (2) Measurements of the ONL were performed at different fields around the entire retinal section (centre, middle and periphery). ImageJ software was used to calculate the ONL thickness, and the mean ONL thickness of the entire retina was compared among the different groups. Data represent the mean±SEM (n=5).CC BY · PubMed Central
Figure 4 Photoreceptors’ density as estimated by ImageJ among the different groups (photoreceptors nuclei number/retinal area). Data represent the mean±SEM (n=3).
Figure 4 Photoreceptors’ density as estimated by ImageJ among the different groups (photoreceptors nuclei number/retinal area). Data represent the mean±SEM (n=3).CC BY · PubMed Central
Figure 5 Gene transcripts of (A) TLR3, (B) NF-κB and (C) IL-18 in the retinas of C57BL/6 untreated, CCL2−/− untreated, CCL2−/− treated with ω-3+ω-6 and CCL2−/− treated with ω-3. Lower levels in TLR3 and NF-κB mRNA were detected by quantitative reverse transcription PCR in the ocular tissue of both treatment groups. The graph is plotted as the mean±SEM (n=4–5).
Figure 5 Gene transcripts of (A) TLR3, (B) NF-κB and (C) IL-18 in the retinas of C57BL/6 untreated, CCL2−/− untreated, CCL2−/− treated with ω-3+ω-6 and CCL2−/− treated with ω-3. Lower levels in TLR3 and NF-κB mRNA were detected by quantitative reverse transcription PCR in the ocular tissue of both treatment groups. The graph is plotted as the mean±SEM (n=4–5).CC BY · PubMed Central
Figure 6 Western blot analysis of (A) TNF-α, (B) IL-17 and (C) IL-18 protein levels in the retinas of C57BL/6 untreated, CCL2−/− untreated, CCL2−/− treated with ω-3+ω-6 and CCL2−/− treated with ω-3. A significant reduction in the protein levels of IL-18 was observed in the ω-3 treatment group only. The graph is plotted as the mean±SEM (n=4-5).
Figure 6 Western blot analysis of (A) TNF-α, (B) IL-17 and (C) IL-18 protein levels in the retinas of C57BL/6 untreated, CCL2−/− untreated, CCL2−/− treated with ω-3+ω-6 and CCL2−/− treated with ω-3. A significant reduction in the protein levels of IL-18 was observed in the ω-3 treatment group only. The graph is plotted as the mean±SEM (n=4-5).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 16

Metadata

Authors
Prokopiou, E., Kolovos, P., Kalogerou, M., Neokleous, A., Papagregoriou, G., Deltas, C., Malas, S., & Georgiou, T.
Affiliations
  • Ophthalmos Research and Educational Institute, Nicosia, Cyprus
  • University of Cyprus (CY)
  • Cyprus Institute of Neurology and Genetics (CY)
Corresponding author
Georgiou, Tassos
Venue
BMJ Open Ophthalmology
Publisher
BMJ
Published
2017-06
Volume
1
Issue
1
Pages
e000056
ISSN
2397-3269 (ISSN-L)
OpenAlex
W2638109236
Cited by
16
References
49
Citations by year
2025: 1 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 1
FWCI
1.60
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • BMJ Open Ophthalmology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Queen's University Belfast
  • Queen's University
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
omega-3 fatty acids, omega-6 fatty acids, dry age-related macular degeneration, eicosapentaenoic acid, arachidonic acid, retinal inflammation, NF-κB, IL-18, outer nuclear layer thickness, retinal regeneration, dietary supplementation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic potential of omega-3 fatty acids supplementation in a mouse model of dry macular degeneration. https://app.cochat.ai/papers/10.1136/bmjophth-2016-000056
The paper
Prokopiou, E., Kolovos, P., Kalogerou, M., Neokleous, A., Papagregoriou, G., Deltas, C., Malas, S., & Georgiou, T. (2017). Therapeutic potential of omega-3 fatty acids supplementation in a mouse model of dry macular degeneration. BMJ Open Ophthalmology. https://doi.org/10.1136/bmjophth-2016-000056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.